Every branded GLP-1 has come with a manufacturer "savings card" at some point, usually promising a copay of around $25. Whether that applies to you, and what it's worth, depends on the drug, your insurance, and whether the program still takes new enrollees. Two of the cards below are closed to new signups, and two cover pills that launched in 2026. Every program is listed side by side, sourced from each manufacturer's own site as of September 2026.
A savings card lowers your copay when your insurance already covers the drug. If you have no coverage at all and are pricing out cash pay, see manufacturer direct-pay instead.
Pills are included
Three GLP-1 pills are on the US market, and all three have savings cards:
- Ozempic tablets (oral semaglutide 1.5, 4, and 9 mg, for type 2 diabetes). Their FDA label is dated January 2026, and they went on sale in the US on May 4, 2026. They are a reformulation, at lower milligram doses, of the oral semaglutide Novo Nordisk used to sell here as Rybelsus. Novo says Rybelsus will continue to be marketed outside the US. The two are not interchangeable mg for mg.
- Wegovy tablets (oral semaglutide, 25 mg maintenance dose, for weight management), approved in December 2025. They run on the same NovoCare savings offer as the Wegovy injection.
- Foundayo (orforglipron, Eli Lilly), approved in April 2026. It is the first non-peptide oral GLP-1 and has no food or water restrictions. It launched with its own savings card.
For how the pills compare beyond price, see comparing the GLP-1 pills.
The rules nearly every card shares
Five eligibility rules show up on almost every card below:
- You need commercial insurance. Every active card requires private or employer coverage that includes the drug. None can be used by anyone enrolled in Medicare, Medicaid, TRICARE, VA, DoD, or any other government health program. That exclusion comes from the federal anti-kickback law, not from the manufacturers, and it applies even if you'd pay cash and skip billing your government plan.
- You must be a U.S. resident aged 18 or older (Lilly's programs also include Puerto Rico).
- The card cuts a copay; it doesn't replace coverage. If your plan doesn't cover the drug, the card either doesn't apply or switches to a much smaller "non-covered" discount (see each row below).
- There's a dollar cap. "As little as $25" is real, but once the program has paid its monthly or yearly maximum, you're back to your normal copay.
- Cards expire and get reissued. Every program below is time-limited (most run through December 31, 2026) and can be renewed, changed, or discontinued at the manufacturer's discretion. Treat every number here as a snapshot and confirm current terms before you rely on one.
The programs, side by side
| Drug (manufacturer) | Form | Status | With covered insurance | Without coverage / uninsured | Annual cap | Enroll |
|---|---|---|---|---|---|---|
| Wegovy (Novo Nordisk) | Injection + oral tablet | Active | As little as $25/mo, capped at $100/mo savings | NovoCare Pharmacy self-pay: $199/mo intro (through 12/31/26), then $349–$399/mo by dose; oral tablet from $149/mo | Set by monthly cap | novocare.com or text SAVE to 83757 |
| Ozempic (Novo Nordisk) | Injection | Active | As little as $25, capped at $100/1-mo, $200/2-mo, $300/3-mo | NovoCare Pharmacy self-pay: $199/mo intro, then $349–$499/mo by dose | Set by monthly cap | novocare.com |
| Ozempic tablets (Novo Nordisk; replaced Rybelsus in the US) | Oral tablet | Active, on sale since May 4, 2026 | As little as $25, capped at $100/1-mo, $200/2-mo, $300/3-mo | NovoCare Pharmacy self-pay: $149/mo (1.5 mg), $199/mo (4 mg), $299/mo (9 mg) | Set by monthly cap | novocare.com |
| Foundayo (orforglipron, Eli Lilly) | Oral tablet | Active, new for 2026 | As little as $25 for a 1- or 3-month supply, capped at $100/1-mo, $200/2-mo, $300/3-mo | Self-pay from $149/mo (lowest dose) up to $349/mo (highest dose, $299 with timely refill) | Up to $1,000/yr, 10 fills/year | foundayo.lilly.com |
| Zepbound (Eli Lilly) | Injection | Active | As little as $25 for a 1–3 month fill, up to 13 fills/year | Commercial plan that excludes it (savings card): as low as $499/mo (single-dose pen) or $299–$449/mo by dose (KwikPen). Uninsured: LillyDirect cash pricing, $299–$449/mo by dose (vial or KwikPen) | Up to $100/mo, ~$1,300/yr (tightened for 2026 from $150/mo, $1,950/yr) | zepbound.lilly.com |
| Mounjaro (Eli Lilly) | Injection | Active | As little as $25 for up to a 3-month fill | Non-covered plans: as low as $499 for a 1-month fill | Up to $150/mo, $1,950/yr; 13 fills/year | mounjaro.lilly.com |
| Trulicity (Eli Lilly) | Injection | Active | As little as $25 for up to a 3-month fill | No published self-pay tier; check LillyDirect | Up to $150/mo, $1,950/yr; 13 fills/year | trulicity.lilly.com/savings-resources |
| Saxenda (Novo Nordisk) | Injection | Discontinued for new enrollees since June 30, 2023 | — | — | — | None; see alternatives below |
| Victoza (Novo Nordisk) | Injection | Discontinued for new enrollees | — | — | — | Not covered by NovoCare's current diabetes savings card |
Figures are snapshots as of September 2026, not quotes. Manufacturers change prices, caps, and eligibility rules without notice, sometimes mid-year, so confirm the live terms on the manufacturer's enrollment page before you count on a number.
Wegovy (semaglutide, Novo Nordisk): injection and tablet
If your commercial plan covers Wegovy, you can pay as little as $25 a month, with savings capped at $100 a month. That applies to both the injection and the oral tablet, which the FDA approved for weight management in December 2025. If you're uninsured or your plan excludes it, NovoCare Pharmacy charges new self-pay patients $199 a month for the 0.25 mg or 0.5 mg starting doses (through December 31, 2026). After that it's $349 a month for 0.25–2.4 mg and $399 a month for the newer 7.2 mg (Wegovy HD) dose. Self-pay for the tablet is $149 for the 1.5 mg starting dose, $199 for 4 mg, and $299 for 9 mg and 25 mg. Enroll at NovoCare.com or by texting SAVE to 83757.
Ozempic (semaglutide, Novo Nordisk): pen and tablets
The Ozempic pen and Ozempic tablets both run on Novo Nordisk's Diabetes Savings Card. With commercial coverage you pay as little as $25, with savings capped at $100 for a 1-month fill, $200 for 2 months, or $300 for 3 months. Your enrollment is valid for up to 48 months, but the Ozempic injection offer has to be redeemed by December 31, 2026.
Self-pay through NovoCare Pharmacy differs by form. For the pen, new patients pay $199 a month for the first two fills of 0.25 mg or 0.5 mg, then $349 a month for 0.25–1 mg and $499 for 2 mg. The tablets cost $149 a month for the 1.5 mg starting dose, $199 for 4 mg, and $299 for 9 mg.
If you already take Rybelsus (3, 7, or 14 mg), the Diabetes Savings Card still lists it as of September 2026, and the 3 mg dose is limited to a 1-month fill per redemption. The card requires an insurance claim, so cash-paying patients can't use it. Ask your prescriber whether to move to Ozempic tablets: the doses don't convert mg for mg, and the label gives switching instructions.
Foundayo (orforglipron, Eli Lilly): the new pill
The FDA approved Foundayo in April 2026 as the first oral GLP-1 built from a non-peptide molecule. That's why you can take it any time of day, without the empty-stomach and 30-minute wait rules that apply to oral semaglutide (Ozempic tablets and Rybelsus). It comes in six doses: 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg.
If your plan covers it, you pay as little as $25 for a 1-month or 3-month supply, capped at $100/1-month, $200/2-month, or $300/3-month, with a $1,000 annual maximum and a 10-fill limit. That annual cap is noticeably tighter than Zepbound's or Mounjaro's. Lilly announced self-pay pricing from $149 a month for the lowest dose when Foundayo launched in April 2026. As of September 2026, Lilly's Foundayo pricing pages list up to $349 a month for the two highest doses ($299 if you refill on schedule, mirroring LillyDirect's Zepbound vial pricing). Enroll at foundayo.lilly.com.
Zepbound (tirzepatide, Eli Lilly)
Zepbound's card has two tracks. If your plan covers it, you can pay as little as $25 for a 1-, 2-, or 3-month fill of the single-dose pen, up to 13 fills a year. Lilly tightened this for 2026, cutting the monthly savings cap from $150 to $100 and the annual cap from $1,950 to $1,300.
If your commercial plan excludes Zepbound, the same card discounts the KwikPen to $299–$449 a month by dose, or the single-dose pen to as low as $499 a month. If you have no insurance at all, you'd use LillyDirect's separate cash channel instead. As of September 2026 it prices both the single-dose vial and the KwikPen at $299 (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg) a month, with the maintenance price conditional on refilling within 45 days (see our direct-pay guide).
Medicare, Medicaid, TRICARE, and VA patients can't use the card. Eligible Medicare Part D beneficiaries may qualify separately for the GLP-1 Bridge demonstration, about $50 a month, which covers Zepbound in the KwikPen form only (see our Medicare GLP-1 coverage guide).
Mounjaro (tirzepatide, Eli Lilly)
Mounjaro is approved for type 2 diabetes. If your commercial plan covers it, you pay as little as $25 per fill, capped at $150 a month, $1,950 a year, and 13 fills. If your plan doesn't cover it, the same card can bring a 1-month fill down to as low as $499, with a higher savings ceiling (up to $647 a month and $8,411 a year) because Mounjaro's list price is a little over $1,000 a month. Government-insured patients are excluded.
Trulicity (dulaglutide, Eli Lilly)
Lilly's older weekly injection uses the same structure as Mounjaro. With Trulicity coverage you pay as little as $25 for up to a 3-month fill, capped at $150/1-month, $300/2-month, or $450/3-month, with a $1,950 annual maximum and a 13-fill limit. Get a card at trulicity.lilly.com/savings-resources or call the program at 1-866-923-1953.
Saxenda (liraglutide, Novo Nordisk): card discontinued
Saxenda's savings card stopped taking new enrollees on June 30, 2023, and Novo Nordisk hasn't brought it back. If you're on Saxenda and cost is the problem, Novo's guidance points patients to a GLP-1 that still has an active savings offer. That's worth raising with your prescriber, since Saxenda's daily dosing and more modest weight loss already make it a less common first choice (see our liraglutide guide). Saxenda is also excluded from Novo's Patient Assistance Program, which is built around diabetes medications.
Victoza (liraglutide, Novo Nordisk): card discontinued
Victoza's copay card is also closed to new signups, and NovoCare's current Diabetes Savings Card explicitly excludes it. Victoza is off Novo Nordisk's 2026 Patient Assistance Program product list too. As of September 2026, the only GLP-1 on that list, apart from the insulin combination Xultophy, is Ozempic injection (Rybelsus and Ozempic tablets aren't listed), so the PAP is no longer a route to free Victoza. Our PAP guide explains how patient assistance programs differ from savings cards.
If none of these apply to you
A savings card only helps if you already have commercial insurance that at least partly covers the drug. It can't get you coverage you don't have, and it excludes anyone on a government plan. Three other paths are worth checking:
- Fix the coverage problem. If your plan denies or restricts the drug, our guides to understanding insurance coverage and checking your formulary cover prior authorization, step therapy, and appeals.
- Price out manufacturer direct-pay. If you have no coverage at all, LillyDirect and NovoCare's self-pay pharmacies sell the same brand product at a flat cash price, which is often cheaper than a capped savings card once you account for the cap.
- Check state and employer options. Some states mandate obesity-drug coverage, and self-funded employers can add coverage voluntarily. See state coverage mandates and making the case to a self-funded employer.
This is general information, not medical or financial advice. Each manufacturer sets its own savings card prices, caps, and eligibility rules and changes them often. Confirm the current terms on NovoCare.com, LillyDirect, or the drug's own site before you enroll or budget around any figure here.